Monoclonal antibodies to clostridia glutamate dehydrogenase
ViroStat has announces the release of new monoclonal antibody pairs to clostridia glutamate dehydrogenase (GDH), validated by enzyme-linked immunosorbent assay (ELISA). These antibodies represent a new set of tools for rapid detection.
Clostridium difficile-associated diarrhoea (CDAD) is the leading cause of nosocomial diarrhoea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces. Thus, rapid detection is crucial to its control. Most rapid tests target the toxins (A & B) produced during the infection.
Another diagnostic target is GDH, an enzyme produced and released during bacterial growth. Studies have shown that adding GDH detection together with toxin detection by enzyme-linked immunoassay (EIA) or polymerase chain reaction (PCR) significantly improves assay specificity.
ViroStat is a primary manufacturer, supplying infectious disease reagents to researchers and rapid test manufacturers. Data sheets for these antibodies can be downloaded from the company website, as can a copy of the new ViroStat catalogue.
Other News
Featured Supplier
Verulam Scientific Ltd is an analytical instrument company providing innovative solutions and emerging technologies to the UK pharmaceutical, environmental, life science, food, clinical and biotechnology markets. We provide laboratories with the equipment and services that are crucial to modern analytical services and research.
Upcoming Events
COVID-19 - The Infection Challenging the World
Online
11-14 May 2021
Lab Innovations 2021
NEC, Birmingham
3-4 November 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
